Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
Genelabs Technologies, Inc. Reports Financial Results for the Second Quarter and First Half of 2007
August 27th, 2007
Genelabs Technologies, Inc. (NASDAQ:GNLB) reported revenues of $4.7 million and a net loss of $0.4 million, or $0.01 per share, for the second quarter of 2007. This compares to revenues of $2.3 million and a net loss of $4.3 million, or $0.24 per share, for the second quarter of 2006. Revenues for the first half of 2007 were $8.3 million, and the net loss was $0.9 million, or $0.03 per share, compared to revenues of $4.0 million and a net loss of $7.7 million, or $0.43 per share, for the first half of 2006. At June 30, 2007, Genelabs had $23.9 million in cash and cash equivalents. At December 31, 2006, Genelabs reported cash and cash equivalents of $18.6 million. ...
Source: Clinical Trials Week (2007-08-27)
|
